ChemT Biotechnology leverages AI to replace the traditional trial-and-error approach to molecular screening. Our proprietary AI-driven cellular drug discovery platform, CelMo, automates the generation of novel cell-modulating small molecules that enable precise and tunable control of cell behavior 24 times faster, boosting biologics yields 5–10x and cutting costs by up to 40%. Already revenue-generating with global partners just 6 months post founding, we're redefining biomanufacturing at scale.